Mothaffar F Rimawi
Baylor College of Medicine · NRG Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mothaffar F Rimawi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:16 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05232916 · Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsGreenwich LifeSciences, Inc. · recruiting · Breast Cancer · principal investigator
- Ph1/Ph2NCT03950570 · ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast CancerOrinove, Inc. · completed · Advanced Solid Tumor, Metastatic Breast Cancer · principal investigator
- Ph2NCT03093350 · TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast CancerBaylor College of Medicine · completed · Breast Cancer · principal investigator
- Ph3NCT02003209 · Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNational Cancer Institute (NCI) · completed · HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advancing towards TRAILBLASER: A Trial of TRAIL-R2/HER2 CART for Metastatic Breast CancerP50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2023 · $312,983 awarded in 2023Grant number is on one of their registry trials
- Translational Breast Cancer Research Training ProgramT32CA203690 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2021 to 2022 · $193,635 awarded in 2022Same name and institution; not confirmed by an ID
- NSABP Participating SitesU10CA118735 · NCI · BAYLOR COLLEGE OF MEDICINE · fiscal years 2010 to 2012 · $61,790 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECTU10CA012027 · NCI · NSABP FOUNDATION, INC. · PI NORMAN WOLMARK · fiscal years 1985 to 2012Named on NCT02003209
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT02003209
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:16 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol · 2012419 citationsRCR 10.3
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.J Clin Oncol · 2019306 citationsRCR 11.1
- 238 citationsRCR 6.0
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.Lancet Oncol · 2014157 citationsRCR 4.4
- 137 citationsRCR 4.3
- Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.J Clin Oncol · 2018123 citationsRCR 4.0
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 202689 citationsRCR 44.5
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Breast Cancer Res Treat · 201881 citationsRCR 2.6
- TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.Clin Cancer Res · 202054 citationsRCR 1.8
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.Clin Cancer Res · 202050 citationsRCR 1.7